How should the FDA evaluate new medications for pain?
|Dear U.S. Pain volunteer advocates, |
We wanted to make you aware of an opportunity to submit public comments to the Food and Drug Administration (FDA). Specifically, the FDA would like the public’s views on two main issues: 1. What criteria the FDA should use to evaluate new opioids to treat pain2. What new incentives are needed to better support and encourage the development of new treatments for pain
On Sept. 17 the FDA held a public hearing called “Standards for Future Opioid Analgesic Approvals and Incentives for New Therapeutics to Treat Pain and Addiction.” While the public hearing has passed, the FDA is accepting written comments until Nov. 18.
How to submit
Written comments are to be submitted to the Division of Docket’s Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Electronic comments can be submitted by using the button below.All comments must be identified with the docket number FDA-2019-N-2514. Please keep in mind that all comments submitted to the docket are public.
Why advocates should engageWe think it is important for people with pain to let FDA know your thoughts on these issues. A number of people and organizations at the hearing said that they thought no new opioids should be allowed on the market. What’s your opinion about this?
People with pain need new options
There has long been a lack of new non-opioid medications approved for pain. We encourage you to tell FDA what impact pain has had on your life and how speeding up the development of new drugs in the pipeline could make a difference to your life and the lives of so many others debilitated by chronic pain. People with pain need to make our voices heard. We encourage you to write into the docket.Sincerely,
Cindy SteinbergNational Director of Policy & AdvocacyU.S. Pain FoundationSubmit comments here!
|U.S. Pain Foundation |
email@example.com | uspainfoundation.org
670 Newfield Street
Middletown, CT 06457